Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

Mary E. Charlson, Peter Pompei, Kathy L. Aleš et al. · Journal of Chronic Diseases · 1987 · 48.8K citations

Prognostic Assessment, Longitudinal Studies, Prognostic Comorbidity +11

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

Surgical Oncology, Recist Guideline, Medicine +9

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo et al. · New England Journal of Medicine · 2018 · 3.7K citations · Full text

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Silvia Novello, Fabrice Barlési, Raffaele Califano et al. · Annals of Oncology · 2016 · 2.6K citations

Medicine, Cancer Management, Pulmonary Blastoma +5

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

David Planchard, Sanjay Popat, Keith M. Kerr et al. · Annals of Oncology · 2018 · 2.2K citations · Full text